Royalty Report: Drugs, Therapeutic, Diagnostic – Collection: 87659

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Therapeutic
  • Diagnostic
  • Disease
  • Cannabis
  • Cancer
  • Nanoparticles
  • Gastrointestinal
  • Pain
  • Ulcer
  • Hormones

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 87659

License Grant
The license to be granted by Licensor to Licensee is a royalty-bearing license under all applicable patent and other proprietary rights of Licensee, including without limitation rights under the Technology and Licensee’s interest in the New Inventions and Joint Inventions to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) the Products in the Field in the Territory.

Subject to the Right of First Refusal and Option below, Licensor shall not license to any third party, and hereby grants an exclusive option to Licensee to license, the Licensor IP Rights to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) naloxone for treatment or prevention of opioid overdose in the Territory.

License Property
Product Pharmaceutical formulations containing the Compound as an active ingredient and the Excipient.

Compound Naloxone or Option Compound and any metabolite, salt, ester, hydrate, anhydride, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, complexes, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, isomer, tautomer, or optically active form of the foregoing.

Option Compound Naltrexone and nalmephene/ nalmefene.

Naloxone is a medication used to block the effects of opioids, especially in overdose.[1] Naloxone may be combined within the same pill as an opioid to decrease the risk of misuse.

Naloxone blocks or reverses the effects of opioid medication, including extreme drowsiness, slowed breathing, or loss of consciousness. An opioid is sometimes called a narcotic.

Field of Use
This agreement pertains to the treatment or prevention of any disease, disorder, state, condition or malady in humans except in the Opioid Field, provided that upon election of Opiant in writing and payment of the Option Fee, the “Field” shall include the Opioid Field.

Naloxone is used to treat a narcotic overdose in an emergency situation. This medicine should not be used in place of emergency medical care for an overdose.

Naloxone is also used to help diagnose whether a person has used an overdose of an opioid.

IPSCIO Record ID: 256780

License Grant
The French Licensor hereby grants to Licensee an exclusive (including with regard to Licensor and its Affiliates) license, with the right to grant sublicenses, under the Licensed Patents and the Licensed Know-How to Exploit the Licensed Compounds and the Licensed Products in the Field in the Territory; and a non-exclusive license to use the Licensors Corporate Names solely as necessary for Licensee to perform its obligations and for no other purpose.
License Property
Licensed Patents
4,883,867 – Detection of reticulocytes, RNA or DNA
6,355,631 – Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
7,652,154 – Method and intermediates for the preparation of derivatives of N (1-benzhydrylazetidin-3-yl)-N-phenylmethylsulfonamide

Licensed Compound means the pharmaceutical compound known as AVE1625 (drinabant), as more specifically described, together with any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug form, racemate, polymorph, chelate, stereoisomer, tautomer or optically active form of any of the foregoing.

Field of Use
Field means the therapeutic emergency treatment of Acute Cannabinoid Overdoses in humans by administration of a pharmaceutical product via any parenteral route of administration. The term “Field” excludes the chronic administration of a therapeutic agent, irrespective of the purpose or route of administration.

IPSCIO Record ID: 189493

License Grant
Licensor hereby grants to the Irish Licensee an exclusive (including with regard to Licensor) worldwide license, with the right to grant sublicenses, under the Licensor Patents, the Product Specific Patents, the Licensor Know-How, and Licensor’s interests in the Joint Patents and the Joint Know-How, to Exploit Products.
License Property
Licensor owns or Controls certain intellectual property relating to the use of intranasal naloxone for a treatment to reverse opioid overdoses.  Naloxone is a medication used to block the effects of opioids, especially in overdose.

Product means any pharmaceutical product or medical device, whether prescription or over-the-counter, marketed for a treatment of opioid overdose containing naloxone, alone or in combination with one or more other active or inactive ingredients, in any intranasal form, presentation, strength or delivery systems; provided, however, that Product shall not refer to any product Controlled, developed, manufactured, marketed, sold, offered for sale, exported, or imported directly or indirectly by a Sublicensee if such Sublicensee’s rights in respect of such product were obtained or developed independently of any sublicense or right granted by Licensee hereunder.

Product Specific Patents
US Application No. 61/953,379    Filing Date 3/14/2014  –  NASAL DRUG PRODUCTS AND METHODS OF THEIR USE
US Application No. 62/022,268    Filing Date 7/9/2014  –    CO-PACKAGED DRUG PRODUCTS

Field of Use
This agreement pertains to the drug industry relating for a treatment of opioid overdose containing naloxone.

IPSCIO Record ID: 344646

License Grant
English Licensor hereby grants to Licensee an exclusive, royalty-bearing licence (with the right to grant sublicenses) under the Licensor Licensed IP to Exploit the Licensor Licensed Compounds and the Licensed Products in the Field in the Territory.

English Licensor hereby grants to Licensee (and its Affiliates and Sublicensees) access to, and a right of reference with respect to, any Regulatory Materials, to the extent Controlled by Licensor at the Commencement Date, for the purposes of Exploiting the Licensor Licensed Compound and Licensed Products in the Field in the Territory. Licensor agrees to execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be reasonably necessary or appropriate in order to effect such right of reference.

License Property
Licensor has discovered and developed a CB1 antagonist compound known as V24343 and owns and controls various data and know how relating thereto.

Licensed Product means any pharmaceutical product containing a Licensor Licensed Compound in any and all forms, presentations, delivery systems, dosages, and formulations.

V24343 means the molecule and structure and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, stereoisomer, tautomer, resinate or optically active form thereof.

Licensor Licensed IP means any and all Licensor Know How including the Licensor Regulatory Materials and Licensor Licensed Compound Information.

Field of Use
ANEB-001 is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

IPSCIO Record ID: 359061

License Grant
Included with this license and collaboration agreement is a license grant upon voluntary termination.

With respect to the applicable Reversion Compounds being terminated, Licensor grants, effective upon such termination, an exclusive even us to Licensor. sub-licensable, worldwide license under the Licensor Reversion Technology to research, develop, import, use, make. have made, offer for sale and sell Reversion Compounds and Reversion Products including as part of a Licensee Combination Therapy in the Field in the Territory.

License Property
Licensors Reversion Technology means Licensor Technology that both was actually used or generated by Licensor or its Affiliates or Sublicensees with respect to the applicable Reversion Compound or Reversion Product, and is necessary to continue development, manufacture or commercialization without unreasonable delay of the applicable Reversion Compound or Reversion Product.

Reversion Compound means NLG919, any Next Generation Compound or any Subsequent Compound.

NLG919 means Licensee’s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.

Next Generation Compound means any Compound other than NLG919 that is invented, by or on behalf of Licensee or its Affiliate, whether solely or jointly, as of the Effective Date or thereafter during the Restriction Period, whether or not pursuant to the Research Plan, that is invented or otherwise the subject of research or preclinical development conducted, by or on behalf of Licensor or its Affiliate or Sublicensee, but excluding the pRED Organization, whether solely or jointly, during the Next Gen Research Term, whether or not pursuant to the Research Plan, the composition of matter, manufacture or use of which is Covered by a Valid Claim of a Licensee Patent or Collaboration Patent; or that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described above.

Field of Use
Field means any use.

Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.

IPSCIO Record ID: 273379

License Grant
The Irish Licensor grants to the Irish Licensee an exclusive license to the Licensor Intellectual Property to import, export, use, other than for formulation development activities, offer for sale and sell the Product in the Field in the Territory.

Licensor grants a worldwide, non-exclusive license to the Licensor Trademark, solely for the purpose of fulfilling Licensees obligations in relation to this Agreement.

License Property
Compound means the active drug substance lorazepam (7-chloro-5-(2-chlorophenyl)-3- hydroxy- l ,3-dihydro-2H-1,4..benzodiazepin-2-one) including all salts, esters, complexes, chelates, hydrates, isomers, stereoisomers, crystalline forms, amorphous forms, prodrugs (including all compounds that are metabolized or dissolve into the same active moiety in the body), solvates, metabolites/metabolic precursors, and pegylated form thereof.

Other Compound means diazepam (7-chloro-l-methyl-5-phenyl-l ,3-dihydro-2H-1 ,4- benzodiazepin-2-one). including all salts, esters, complexes, chelates, hydrates, isomers, stereoisomers, crystalline forms, amorphous forms, prodrugs (including all compounds that are metabolized or dissolve into the same active moiety in the body), solvates, metabolites/metabolic precursors, and pegylated form thereof.

Product means the nasal formulation of Product Intermediate incorporated or filled into a Device.

Buccal Formulation means formulations of Product Intermediate for administration by placing in the mouth for absorption through the cheek, the gum or the upper or lower inside lip without swallowing, achieved by means of a muco adhesive, including but not limited to any specific formulation that may be selected for commercialization.

Field of Use
The product is used or useful in the manufacture and use of products containing nanoparticles.

Field means the use as a prescription or over-the-counter pharmaceutical product in humans, specifically excluding diagnostic use.

Licensee acquired global rights to a novel nasal lorazepam formulation for the treatment of emergency seizures in epilepsy patients.

IPSCIO Record ID: 279342

License Grant
Licensor hereby grants to the Puerto Rico Licensee in the Field an exclusive (even as to Licensor, other than as set forth in this agreement (Retained Rights)) license under the Licensor Technology and Joint Technology, with the right to sublicense as set forth in this agreement (Sublicenses), to make, have made, use, Develop, sell, offer to sell, have sold, import, export, and otherwise exploit and Commercialize the Compound and Products in the Territory. Licensee acknowledges that with respect to those Licensor Patent Rights that are Controlled by Licensor pursuant to the Third Party Agreements, the foregoing license is subject to the rights of the Third Party licensors under such Third Party Agreements.
License Property
Compound means R-methyinaltrexoun (R-MNTX) which is chemically defined as morphinanium, 17R, 17-(cyclopropylmethyl)-4, 5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5a)-(9C1), and its pharmacologically acceptable salts, together with their solvates, hydrates, hemihydrates, metabolites, pro-drugs, esters, and if applicable, any isomers or racemates thereof, but excluding any of the foregoing olecules whose primary mechanism of action is as an opioid agonist. The “Compound” does not include the Excluded Molecules.

Licensor Patent Rights are identified as
4,719,215 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
4,861,781 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
5,102,887 – Method for reducing emesis and nausea induced by the administration of an emesis causing agent

To relieve pain, narcotic medications such as morphine activate specific opioid receptors located in the central nervous system – the brain and spinal cord. Opioids, however, also interact with these receptors outside of the central nervous system, resulting in side effects, which can be debilitating, including constipation, urinary retention and severe itching. MNTX is designed to block peripheral opioid receptors whose activation causes these side effects. As MNTX does not cross the blood-brain barrier, it does not interfere with brain-centered pain relief.

Field of Use
The agreement is for the joint development and commercialization of methylnaltrexone (MNTX) for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. These medical conditions are major therapeutic challenges in the management of gastrointestinal function in individuals treated with opioids for pain or in patients following serious or prolonged surgeries.

IPSCIO Record ID: 221363

License Grant
The Germany Licensor grants to the Irsih Licensee the exclusive, non-assignableright and license to use the Licensor IPR Package

(a) to Commercialize the Product in the Territory;

(b) to Manufacture in any country the quantities of Product required for Commercialization in the Territory; and

(c) to Develop the Product for Commercialization in the Territory.

License Property
“Product” means any pharmaceutical product containing the API
“API” means the active pharmaceutical ingredient macimorelin acetate, and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug, racemate, polymorph, chelate, stereoisomer, tautomer, or optically active form of any of the foregoing.

Macrilen™ (macimorelin) is an orally-active ghrelin agonist that stimulates the secretion of growth hormone. Macrilen™ (macimorelin) has been granted orphan drug designation by the FDA for the evaluation of growth hormone deficiency. On December 20, 2017, the FDA granted Licensor marketing approval for Macrilen™ (macimorelin) to be used in the diagnosis of patients with adult growth hormone deficiency (“AGHD”).

“Adult Indication” means assessing GHD in adults.

“GHD” means growth hormone deficiency.

AGHD reportedly affects approximately 60,000 adults across the U.S. and Canada. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life as well as an increase of cardiovascular risks.

Licensor Trademark” means the Macrilen trademark registered in the Territory and any accompanying logos, trade names, trade dress and/or other indicia relating to the Product Controlled by the Licensor.

Field of Use
This agreement pertains to the drug industry relating the evaluation of growth hormone deficiency to be used in the diagnosis of patients with AGHD.  MACRILEN(macimorelin) is a prescription oral solution that is used to test for adult growth hormone deficiency (AGHD).

IPSCIO Record ID: 372413

License Grant
The Licensor Parties grant an exclusive, world-wide license to make, have made, use, lease, import, offer for sale and sell Licensed Products and to use the method under Patent Rights and Technical information, to the extent not prohibited by other patents, in the Field of Use.
License Property
The Licensor Parties are the owners of the Method Patent and a pending patent entitled Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists and one Licensor is the owner/Sponsor of IBD FDA IND#, FDA orphan drug designation x-2969 and a pending patent for Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists.
Field of Use
The term Field of Use means development, production, use, and storage of Licensed Products, alone or in combination with other treatments, for the prevention and/or treatment of Crohn's disease and other inflammatory and ulcerative diseases of the bowel.
Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract from the mouth to the anus

IPSCIO Record ID: 324330

License Grant
The purpose of this amendment is to reflect the updated supply agreement between the Parties relating to the supply of the API Macimorelin acetate;  grant the Licensee of Ireland a joint ownership interest in the German Licensor Patent Rights and Licensor Trademarks; amend responsibility between the Parties for the pediatric clinical trial for the Pediatric Indication; make a payment to Licensor; and,  modify the future payment obligations.  Pediatric Indication means assessing GHD in Children.

The German Licensor grants to the Licensee of Ireland a joint ownership interest in the Licensor Patent Rights and Trademarks (Joint Ownership Interest) and a non-assignable right and license to use the Licensor IPR Package (Licensors know-how and Intellectual Property rights)
a)
to Commercialize the Product in the Territory;
b)
to Manufacture in any country the quantities of Product required for Commercialization in the Territory; and
c)
to Develop the Product for Commercialization in the Territory.

With this amendment, Licensee now has a joint ownership interest under the Licensor Patent Rights and the Licensor Trademarks to carry out development, manufacturing, registration and commercialization of the Product in the Territory.

License Property
Licensor owns or has the exclusive right to certain technology, intellectual property rights, regulatory files and confidential and/or proprietary information relating to the Product macimorelin acetate.

Patents are or relate to Growth Hormone Secretagogues;  Methods and kits to diagnose Growth Hormone Deficiency;  Method of Assessing Growth Hormone Deficiency Comprising Oral Administration of a Macimorelin Containing Composition and Collecting One or Two Post-administration Samples;  Use of Macimorelin in Assessing Growth Hormone Deficiency in Children;  A novel peptide-mimetic GH secretagogue with potent and selective GH-releasing activity in man by Broglio et al; Targeting the Ghrelin Receptor; and, GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.

API means the active pharmaceutical ingredient macimorelin acetate, and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug, racemate, polymorph, chelate, stereoisomer, tautomer, or optically active form of any of the foregoing.

Trademark means the Macrilen trademark registered in the Territory and any accompanying logos, trade names, trade dress and/or other indicia relating to the Product Controlled by Licensor.

Macimorelin (INN), or Macrilen (trade name) is a drug being developed for use in the diagnosis of adult growth hormone deficiency.

Field of Use
Macrilen works by stimulating the release of growth hormone (GH) in the body. Macrilen is used as part of a medical test to measure growth hormone (GH).

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.